See more : 1847 Holdings LLC (EFSH) Income Statement Analysis – Financial Results
Complete financial analysis of NeuroPace, Inc. (NPCE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeuroPace, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Intact Financial Corporation (IFCZF) Income Statement Analysis – Financial Results
- NewRiver REIT plc (NRR.L) Income Statement Analysis – Financial Results
- Destiny Tech100 Inc. (DXYZ) Income Statement Analysis – Financial Results
- Husqvarna AB (publ) (HUSQ-B.ST) Income Statement Analysis – Financial Results
- Dilip Buildcon Limited (DBL.BO) Income Statement Analysis – Financial Results
NeuroPace, Inc. (NPCE)
About NeuroPace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 65.42M | 45.52M | 45.18M | 41.14M | 36.97M |
| Cost of Revenue | 17.30M | 13.03M | 11.75M | 10.87M | 10.51M |
| Gross Profit | 48.12M | 32.49M | 33.44M | 30.27M | 26.46M |
| Gross Profit Ratio | 73.56% | 71.38% | 74.00% | 73.59% | 71.58% |
| Research & Development | 20.78M | 21.95M | 18.21M | 15.70M | 18.29M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 54.52M | 51.34M | 38.96M | 27.63M | 30.20M |
| Other Expenses | 0.00 | -337.00K | -5.38M | 218.00K | 1.28M |
| Operating Expenses | 75.30M | 73.29M | 57.17M | 43.32M | 48.50M |
| Cost & Expenses | 92.60M | 86.31M | 68.92M | 54.19M | 59.00M |
| Interest Income | 3.05M | 1.58M | 448.00K | 41.00K | 261.00K |
| Interest Expense | 8.52M | 7.53M | 7.41M | 11.49M | 9.49M |
| Depreciation & Amortization | 1.61M | 2.99M | 296.00K | 312.00K | 421.00K |
| EBITDA | -22.83M | -36.57M | -28.37M | -12.48M | -20.07M |
| EBITDA Ratio | -34.90% | -86.89% | -62.80% | -30.34% | -54.28% |
| Operating Income | -27.17M | -40.79M | -23.74M | -13.05M | -22.03M |
| Operating Income Ratio | -41.54% | -89.62% | -52.54% | -31.72% | -59.59% |
| Total Other Income/Expenses | -5.78M | -6.29M | -12.34M | -11.23M | -7.94M |
| Income Before Tax | -32.96M | -47.08M | -36.08M | -24.28M | -29.97M |
| Income Before Tax Ratio | -50.38% | -103.43% | -79.85% | -59.02% | -81.07% |
| Income Tax Expense | 0.00 | 6.29M | 2.03M | 11.70M | 10.77M |
| Net Income | -32.96M | -53.37M | -38.11M | -35.98M | -40.74M |
| Net Income Ratio | -50.38% | -117.25% | -84.34% | -87.47% | -110.19% |
| EPS | -1.27 | -2.17 | -1.56 | -1.51 | -1.71 |
| EPS Diluted | -1.27 | -2.17 | -1.56 | -1.51 | -1.71 |
| Weighted Avg Shares Out | 25.85M | 24.59M | 24.45M | 23.83M | 23.83M |
| Weighted Avg Shares Out (Dil) | 25.85M | 24.59M | 24.45M | 23.83M | 23.83M |
NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting
MOUNTAIN VIEW, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will have a substantial presence at the...
NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
MOUNTAIN VIEW, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced will present at the Piper Sandler 35th Annual Healthcare Conference,...
NeuroPace, Inc. (NPCE) Q3 2023 Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Irina Ridley - Chief Legal Officer and Head of Investor Relations Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer...
NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
Third quarter 2023 revenue of $16.4 million, an increase of 47% year-over-year Full-year revenue guidance increased to $62.5-$63.5 million, up from $59-$61 million Cash burn reduced to $2.2 million in the third quarter of 2023, relative to $4 million in...
NeuroPace Announces RNS System Enhancements Designed to Streamline Care
- Upgraded nSight Platform Improves Clinicians' Ability to Track, Review and Evaluate Patient Data - - ‘Simple Set Programming' Enables Complete Programming Set Transfer Directly to RNS Tablet - - FDA Approval of Smaller, Portable and Simpler Tablet Remote Monitor...
NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
MOUNTAIN VIEW, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of...
NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference
MOUNTAIN VIEW, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced participation in a fireside chat discussion at the upcoming 2023...
NeuroPace: A Speculative Epilepsy Play
NeuroPace aims to improve the lives of epilepsy patients with its remote monitoring system. The company's RNS system offers personalized and real-time treatments for epilepsy patients. NeuroPace has seen improved commercial traction and increased sales guidance but still faces significant...
NeuroPace to Participate in Upcoming Investor Conferences
- Wells Fargo 2023 Healthcare Conference - - Morgan Stanley 21 st Annual Global Healthcare Conference - - Lake Street Capital Markets 7 th Annual Best Ideas Growth Conference - MOUNTAIN VIEW, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeuroPace,...
NeuroPace, Inc. (NPCE) Q2 2023 Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Irina Ridley - Chief Legal Officer and Head of Investor Relations Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer...
Source: https://incomestatements.info
Category: Stock Reports